Related Experiment Video

Updated: May 17, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute

O G Ottmann, R A Larson, H M Kantarjian

    Leukemia
    |November 10, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
    09:02

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

    Published on: July 31, 2016

    Related Experiment Videos

    Last Updated: May 17, 2026

    A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
    09:52

    A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

    Published on: December 4, 2018

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
    09:02

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

    Published on: July 31, 2016

    Related Concept Videos

    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

    Articles linked to this work by shared authors, journal, and citation graph.

    The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

    Leukemia·2023

    [Interdisciplinary COVID board for patients with SARS-CoV-2-triggered hyperferritinemic Inflammation].

    Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020

    The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

    Leukemia·2020

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Leukemia·2020

    Cancer patients' needs for virtues and physicians' characteristics in physician-patient communication: a survey among patient representatives.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2018

    Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

    Leukemia·2018

    Predicting long-term survival in primary myelofibrosis.

    Leukemia·2026

    Targeting the mitochondrial complex I subunit NDUFS2 potentiates FLT3 inhibition in acute myeloid leukaemia with FLT3 internal tandem duplication.

    Leukemia·2026

    Targeting the eIF4F translation initiation complex disrupts BCR::ABL1 translation and overcomes drug resistance in CML.

    Leukemia·2026

    Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms.

    Leukemia·2026

    Inhibition of PHB2/PINK1-mediated mitophagy potentiates venetoclax activity in acute myeloid leukemia.

    Leukemia·2026

    Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies.

    Leukemia·2026

    Outcomes and prognostic factors in dogs with subcutaneous and intramuscular hemangiosarcoma treated with hypofractionated radiation therapy and chemotherapy.

    Frontiers in veterinary science·2026

    Tumefactive Demyelination in Older Adults: Diagnosis and Misdiagnosis.

    International journal of MS care·2026

    Catheter-related bloodstream infection with coagulase-negative staphylococci in hematological malignancy.

    Infectious diseases (London, England)·2026

    Cytological Findings and Diagnostic Pitfalls of a Rare Tumor Arising From a Rare Site: "The Story of Chondromyxoid Fibroma of Great Toe".

    Diagnostic cytopathology·2026

    Aging-enhanced accumulation of fibroblasts excludes oligodendrocytes in demyelinated lesions.

    Journal of neuroinflammation·2026

    Ribosome biogenesis and selective translational control as oncogenic vulnerabilities in hematologic malignancies.

    Molecular cancer·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us